| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1535-7163.MCT-04-0243 |
| P698 | PubMed publication ID | 15897248 |
| P50 | author | Brooke T. Mossman | Q28112928 |
| Camillo Porta | Q37393105 | ||
| Nicholas H. Heintz | Q109339637 | ||
| P2093 | author name string | Tara Sabo-Attwood | |
| Luciano Mutti | |||
| Maria E Ramos-Nino | |||
| Giovina Vianale | |||
| P433 | issue | 5 | |
| P304 | page(s) | 835-842 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. | |
| P478 | volume | 4 |
| Q55042984 | A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. |
| Q36952781 | A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells. |
| Q42575346 | A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance |
| Q37070229 | Advances in the systemic therapy of malignant pleural mesothelioma |
| Q35684875 | An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. |
| Q28393611 | Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways |
| Q28391676 | Cellular and molecular parameters of mesothelioma |
| Q28393560 | Current issues in malignant pleural mesothelioma evaluation and management |
| Q37281015 | Expression of cancer-associated molecules in malignant mesothelioma |
| Q40032657 | Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas. |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q39864601 | Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates. |
| Q26859274 | New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas |
| Q33529876 | Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent |
| Q34360248 | Overview of the biochemical and genetic processes in malignant mesothelioma. |
| Q24612464 | Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth |
| Q37307815 | Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma |
| Q37179384 | Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies. |
| Q36425940 | Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma |
| Q24658316 | SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis |
| Q28384049 | Targeting the MEK1 cascade in lung epithelium inhibits proliferation and fibrogenesis by asbestos |
| Q41878253 | Unique uptake of acid-prepared mesoporous spheres by lung epithelial and mesothelioma cells |
Search more.